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The utility of external beam radiotherapy for the treatment of malignant brain tumours is compromised by the need to avoid
excessive radiation damage to normal CNS tissues. This review describes the current status of targeted radiotherapy, an alternative
strategy for brain tumour treatment that offers the exciting prospect of increasing the specificity of tumour cell irradiation.
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Even with aggressive multi-modality treatment strategies, the life
expectancy for patients with glioblastoma multiforme (GBM), the
most common and virulent primary brain tumour, is less than a
year from the time of diagnosis (Stewart, 2002). The vast majority
of glioma patients experience local recurrence, with a median
survival of only 16–24 weeks for those with recurrent disease
(Wong et al, 1999). Conventional radiotherapy continues to play a
primary role in brain cancer treatment; however, its lack of tumour
specificity is a severe limitation of this form of therapy. Owing to
its nonspecific nature, toxicity to normal brain limits the radiation
dose that can be delivered to tumour cells, and compromises the
quality of life of the few longer-term survivors.
An emerging approach for brain tumour treatment is targeted
radiotherapy, a strategy that utilises a molecular vehicle to
selectively deliver a radionuclide to malignant cell populations.
An important consideration is to match the decay properties of the
radionuclide with the characteristics of the tumour. The two most
commonly utilised radionuclides in targeted radiotherapy,
131I and
90Y, emit beta particles, which deposit 95% of their energy within
0.992 and 5.94mm, respectively (Hopkins et al, 1998). Radiation of
this type might be best suited for treating tumour that may be
present in the 2-cm rim around the brain tumour resection cavity,
where most gliomas recur. On the other hand, alpha particles have
a tissue range of only a few cell diameters and might be ideal for
elimination of the small clusters or single glioma cells that can
occur 4–7cm from the primary tumour site (Goldbrunner et al,
1999). Alpha particles could potentially enhance the therapeutic
potential for minimal residual disease by maximising the radiation
dose received by these relatively small tumour foci, while sparing
normal CNS tissues.
Although many types of labelled molecules have been explored
for targeted cancer radiotherapy, investigations in brain tumour
patients have almost exclusively utilised monoclonal antibodies
(mAbs) as the targeting vehicle. Brain-tumour-associated mole-
cular targets that have been evaluated for radioimmunotherapy
include the epidermal growth factor receptor (Brady et al, 1992)
and the human neural cell adhesion molecule (NCAM), which is
present both on glioma as well as normal neural tissue (Hopkins
et al, 1998). However, the vast majority of targeted radiotherapy
studies in brain tumour patients have utilised radiolabelled mAbs
reactive with the tenascin molecule (Table 1).
TENASCIN AND ANTI-TENASCIN MABS
Tenascin-C is a hexabrachion polymorphic glycoprotein that is
overexpressed in the extracellular matrix in high-grade gliomas as
well as other tumour types. The expression of tenascin increases
with advancing tumour grade, with more than 90% of glioblastoma
multiforme biopsies exhibiting very high levels of tenascin
expression. Tenascin-C expression occurs primarily around
tumour-supplying blood vessels, with this staining pattern
becoming more pronounced with increasing tumour grade
(Herold-Mende et al, 2002). Furthermore, in WHO II and III
gliomas, there appears to be a correlation between perivascular
staining and earlier tumour recurrence. The mAb BC-4 binds to an
epitope within the epidermal growth factor (EGF)-like repeat
found on all tenascin isoforms, while BC-2 reacts with an epitope
found on the alternatively spliced fibronectin type III repeats A1
and A4, which share 83% homology (Balza et al, 1993). The anti-
tenascin mAb developed by our group, 81C6 (Bourdon et al, 1983),
binds to an epitope within the alternatively spliced fibronectin type
III CD region. In the following sections, the current status of
targeted brain tumour radiotherapy with these mAbs, both directly
labelled and as part of a pretargeting strategy, will be reviewed.
ANTI-TENASCIN MAB 81C6
In order to exploit the potential utility of tenascin as a molecular
target for radioimmunotherapy, mAb 81C6, a murine IgG2b, was
developed. The ability of murine 81C6 to selectively localise and
treat human glioma xenografts was investigated extensively in
rodent models before the initiation of clinical studies with this
labelled mAb (Wikstrand et al, 2001). Three observations from
diagnostic-level investigations performed in glioma patients had
an influence on the design of our subsequent targeted radiotherapy
protocols. First, levels of
131I-labelled 81C6 in tumour biopsies
were up to five times higher than a co-injected
125I-labelled
nonspecific mAb, and up to 200 times higher than those in normal
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labelled 81C6 was both selective and specific. Second, intracarotid
injection did not significantly increase tumour delivery compared
with intravenous administration (Zalutsky et al, 1990). And third,
an mAb protein escalation study demonstrated that intravenous
administration could not be used to deliver therapeutically useful
levels of labeled mAb to tumour without excessive dose to liver and
spleen, normal organs that express tenascin (Schold et al, 1993).
This led us to focus on a compartmental approach involving direct
administration of radiolabelled 81C6 mAb into surgically created
tumour resection cavities.
Iodine-131-labelled 81C6 clinical trials
Our clinical experience with
131I-labelled 81C6 mAb currently
includes over 300 patients who have received the labelled mAb by
direct injection into a surgically created resection cavity via a
Rickham reservoir and catheter placed at the time of resection. The
entry criteria for parallel phase I studies in patients with recurrent
and newly diagnosed malignant glioma included: histopathological
confirmation of diagnosis, demonstration of tumour reactivity
with 81C6 by immunohistochemistry, a maximum of 1cm residual
enhancement on postoperative MRI, and tumor localisation within
the supratentorial compartment. Patency of the catheter and
intactness of the resection cavity was confirmed by radionuclide
imaging prior to treatment, and patients received a saturated
solution of potassium iodide to block thyroid uptake of radio-
iodine that might be released from the labelled mAb. Most patients
received systemic chemotherapy after the radioimmunotherapy
procedure, and newly diagnosed patients also received external
beam radiotherapy.
The phase I study of recurrent disease enrolled 34 patients,
including 26 with GBM (Bigner et al, 1998). The administered dose
of
131I-labelled 81C6 ranged from 740 to 4440MBq (20–120mCi),
and a maximum tolerated dose of 3700MBq (100mCi) was
established. Dose-limiting toxicity was neurologic. The median
survival for patients with recurrent GBM and for all patients
treated was 56 and 60 weeks, respectively. In the parallel phase I
study in patients with newly diagnosed brain tumours, a total of 42
patients were treated including 32 with glioblastoma multiforme
(Cokgor et al, 2000). The administered activity of
131I-labelled
81C6 ranged from 740 to 6660MBq (20–180mCi). A maximum
tolerated dose of 4440MBq (120mCi) was established, with dose-
limiting toxicity again being neurologic. Reversible haematologic
toxicity was observed in seven patients. Patient-specific dosimetry
calculations indicated that the 2-cm thick region surrounding the
resection cavity interface received an average radiation dose of 32
Gy (range 2–59Gy) (Akabani et al, 2000). The median survival for
patients with GBM and all patients was highly encouraging at 69
and 79 weeks, respectively.
A phase II trial was then conducted in patients with newly
diagnosed malignant glioma at an administered activity of
4440MBq (120mCi) of
131I-labelled murine 81C6 (Reardon et al,
2002). In all, 33 patients were enrolled including 27 with GBM.
Treatment-related neurotoxicity was observed in five patients and
reversible haematologic toxicity occurred in nine patients. It
should be noted that irreversible neurotoxicity was associated with
the resection cavity being either contiguous or adjacent to the
compromised CNS functional centre. The median survival
achieved for patients with GBM and all patients enrolled in this
trial was 79 and 87 weeks, respectively. These results were
compared to those predicted by a recursive partitioning model
(Curran et al, 1993). For example, this model predicted a median
survival of 55 weeks for newly diagnosed GBM patients less than 50
years old, while in our study an 87-week median survival was
achieved. Likewise, newly diagnosed GBM patients over 50 years
old with a Karnofsky performance status greater than 70% were
predicted to have a median survival of 39 weeks compared with 65
weeks for those in that category in our study.
Other methodologies such as stereotactic radiosurgery and
125I
interstitial brachytherapy also have been investigated for deliver-
ing a boost radiation dose to tumour, and the prolonged survival
achieved in this phase II study compared favourably to these
approaches. However, an important distinction between targeted
radiotherapy with
131I-labelled 81C6 and these other techniques
was with regard to the need for re-operation to debulk radiation
necrosis and to relieve symptomatic mass effect. Re-operation
rates for brachytherapy and radiosurgery have been reported to be
in the 30–60% range, while only 2% of the 109 combined patients
on our phase I and II trials required re-operation for symptomatic
radionecrosis.
Owing to regulatory constraints, radioiodinated mAb was given
based on
131I activity rather than on a calculated radiation dose to
the resection cavity margins. Dosimetry calculations indicated that
this critical parameter could vary considerably due to differences
in the rate of clearance of radioactivity from the resection cavity
and the resection cavity volume. In the 42 patients entered on the
phase I newly diagnosed trial, radionuclide residence times in the
cavity ranged from 10 to 113h, and cavity volumes from 2 to
81cm
3 (Akabani et al, 2000). This led to average radiation dose
deposited in the 2-cm resection cavity margin ranging from 3 to
59Gy.
A 16-patient subset of these newly diagnosed glioma patients
experienced progressive changes on serial MRI images and had
Table 1 Summary of targeted radiotherapy clinical trials in brain tumour patients
Radiotherapeutic Design Patients
a Toxicities
b Survival (weeks) Reference
I-131 81C6 murine mAb Phase I 34 (26 GBM) recurrent Neuro Heme 60 (56 GBM) Bigner et al (1998)
I-131 81C6 murine mAb Phase I 42 (32 GBM) newly diagnosed Neuro 79 (69 GBM) Cokgor et al (2000)
I-131 81C6 murine mAb Phase II 33 (27 GBM) newly diagnosed Neuro Heme 87 (79 GBM) Reardon et al (2002)
At-211 81C6 chimeric mAb Phase I 17 (14 GBM) recurrent None 60 Zalutsky et al (2002)
I-131 BC-2 or BC-4 mAb Phase II 91 (74 GBM) None 4184 AA Riva et al (2000)
3–10 cycles 44 recurrent 76 GBM
47 newly diagnosed
Y-90 BC-2 or BC-4 mAb Phase II 43 (35 GBM) None 360 AA Riva et al (2000)
3–5 cycles 80 GBM
Y-90 or I-131 BC-4 mAb Phase II 37 (24 GBM) Neuro 68 GBM Goetz et al (2003)
Mean, three cycles
BC-4 mAb, Y-90 biotin Phase I 24 (16 GBM) recurrent Neuro 76 AA Paganelli et al (2001)
two cycles 50 GBM
BC-4mAb, Y-90 biotin Phase II 8 GBM None 134 Grana et al (2002)
two cycles
aGBM¼glioblastoma multiforme; AA¼anaplastic astrocytoma.
bNeuro¼neurological toxicity; Heme¼haemtatological toxicity.
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histopathology and the radiation dose delivered to the 2-cm cavity
margin. Patients receiving a dose less than 44Gy generally had
tumour recurrence, while those receiving more than 44Gy to the 2-
cm margin had a greater incidence of radiation necrosis. In an
attempt to maximise local tumour control while minimising
normal brain radionecrosis, we have now initiated another phase I
study in which newly diagnosed patients are given an activity level
of
131I-labelled 81C6, based on a prior dosimetry study, calculated
to deliver an average of 44Gy to the resection cavity margins. To
date, 17 patients have been treated on this protocol; however, the
median follow up period is not sufficient to provide meaningful
survival data.
Astatine-211 labelled chimeric 81C6 clinical trial
An important variable for targeted brain tumour radiotherapy
is the nature of the radiation emitted by the radionuclide.
Although use of molecules labelled with
131I or other beta emitters
can increase the selectivity of tumour cell irradiation compared
with external beam irradiation, both approaches have similar
radiobiological effectiveness. An advantage of alpha particles
such as those emitted by the 7.2-h half-live radiohalogen
211
At is that they are high linear energy transfer (LET) radiation,
with considerably higher cytotoxicity. Cell culture experiments
have demonstrated that human tumour cell lines could be
killed with only a few alpha particle traversals per cell
(Zalutsky and Vaidyanathan, 2000). Furthermore, the cytotoxicity
of alpha particles is nearly independent of dose rate, oxygen
concentration and cell cycle stage. As tenascin expression is
perivascular, combining anti-tenascin mAb 81C6 with a radio-
nuclide that emits short-range radiation might be a particularly
effective approach, in that it could act as a vascular targeted
therapeutic (Akabani et al, 2002). In this way, it might be
possible to also kill tumour cells indirectly by compromising their
blood supply.
A phase I trial is currently being performed to determine
the maximum tolerated dose, pharmacokinetics and objective
responses to
211At-labelled chimeric 81C6 administered into
surgically created glioma resection cavities in recurrent glioma
patients (Zalutsky et al, 2002). The chimeric construct has
human IgG2 constant region domains and was selected for
this protocol because its stability in vivo was shown to be
considerably higher than that of murine 81C6 (Reist et al, 1998).
The
211At was produced at the Duke University Medical Center
cyclotron and the mAb was labelled with preservation of
immunoreactivity by reaction with N-succinimidyl 3-[
211At]astato-
benzoate. To date, 17 patients (three anaplastic oligodendroglioma,
14 glioblastoma multiforme) have received 10mg of mAb labelled
with escalating activities (74MBq, n¼5; 148MBq, n¼6; 248MBq,
n¼5; 370MBq, n¼1) of
211At-labelled chimeric 81C6. As this
was the first clinical trial of any
211At-labelled radio-
therapeutic, demonstration of in vivo stability and safety were
particularly important. Serial blood counting and imaging
were performed and indicated very low levels of leakage of
211
At from the surgical resection cavity. Less than 0.2% of the injected
dose was found in the blood pool and more than 95% of the
211At
decays occurred within the tumour resection cavity. Cavity
interface radiation doses were in the range of 150–35000Gy
(2986Gy average dose) compared with 0.01Gy for normal organs
including tenascin-expressing spleen and liver. Encouraging
responses have been obtained with a median survival of 60 weeks
observed in all patients. Particularly encouraging is the fact that
two patients with recurrent GBM survived for more than 150
weeks, and a patient with recurrent anaplastic oligodendroglioma
is now approximately 215 weeks from treatment. The maximum
tolerated dose of
211At-labelled chimeric 81C6 has yet to be
defined.
STUDIES WITH BC-2 AND BC-4 ANTI-TENASCIN
MABS
(Riva et al, 2000) have been evaluating the efficacy of
131I-labelled
and
90Y-labelled BC-2 and BC-4mAbs for the locoregional
treatment of malignant gliomas. In these protocols, no distinction
was made between the two mAbs. The phase II study with
131I
involved 91 patients including 74 with glioblastoma and nine with
anaplastic astrocytoma. At the time of treatment, 52 patients were
classified as having small (less than 2cm
3) or undetectable residual
tumour, with the remainder having a larger tumour mass. The
study population consisted of 47 newly diagnosed and 44 recurrent
tumours. Patients received three to 10 cycles of
131I-labelled mAb,
at intervals of either 1 or 3 months, with a cumulative administered
activity of up to 20.35GBq (550mCi). The median survival was
446 months in anaplastic astrocytoma and 19 months in
glioblastoma, with no distinction made between newly diagnosed
and recurrent patients groups. The response rate in glioblastoma
patients was better in those with small volume (56.7%) compared
with larger tumours (17.8%).
A subsequent study was performed using
90Y in order to
investigate the potential effects of using a radionuclide emitting
beta particles with greater tissue penetration (Riva et al, 2000). In
this phase II investigation, 43 patients were treated, including six
with anaplastic astrocytoma and 35 with glioblastoma. In all, 16
were classified as having small volume or minimal disease at the
time of treatment. Patients received between three and five cycles
of
90Y-labelled mAbs with a cumulative activity of up to 3.145GBq
(85mCi). The median survival for patients with anaplastic
astrocytoma and glioblastoma was 90 months and 20 months,
respectively. The response rate in glioblastoma patients was 26.3%
in those with bulky disease compared with 56.3% for those with
smaller lesions.
In a more recent study, the therapeutic potential of
131I- and
90Y-
labelled BC-4mAb were evaluated in 37 patients, consisting of 13
with astrocytoma WHO grade III and 24 with WHO grade IV
histology (Goetz et al, 2003). Multiple cycles of labelled mAbs were
administered (mean, three per patient) at various activity levels.
The median survival for glioblastoma patients was 17 months. No
attempt was made to stratify analyses according to the radio-
nuclide used or whether the patients had recurrent or newly
diagnosed lesions.
These clinical studies are important in that they confirm the
potential of locoregionally administered labelled mAbs as a means
for improving the survival of patients with malignant brain
tumours. The low incidence of side effects, even after multiple
cycles, also is encouraging. However, it remains to be ascertained
whether use of the higher energy beta emitter
90Y and multiple
cycles of labelled mAb results in a significant improvement in
therapeutic efficacy compared with a single dose of
131I-labelled
mAb.
PRETARGETED RADIOIMMUNOTHERAPY
One of the limitations of directly labelled mAbs for targeted
radiotherapy is that as a consequence of their macromolecular
size they diffuse slowly through tissue, hampering their delivery
to tumour cells distant from their site of injection. An attractive
strategy to compensate for the large size of mAbs is pretargeting,
a procedure in which the mAb is administered first, followed
after an appropriate time interval by the injection of a radio-
labelled low molecular weight vehicle. The most common
approach attempts to exploit the extraordinarily high affinity of
avidin or streptavidin for the 244Da vitamin, biotin. A three-step
avidin-biotin based regimen has been investigated in glioma
patients who first received biotinylated BC-4mAb, followed 24h
later by avidin, and finally, after an additional 18h, a
90Y-labelled
biotin conjugate.
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patients with recurrent glioma and the three reagents were
administered via a catheter placed into the surgical resection
cavity (Paganelli et al, 2001). In all, 16 patients with glioblastoma
and eight with anaplastic astrocytoma were treated with two cycles
administered 8–10 weeks apart. The maximum tolerated dose was
1.11GBq (30mCi) of
90Y-labelled DOTA, biotin with neurologic
toxicity being the dose-limiting factor. After the second operation,
median survival was 19 and 11.5 months in patients with anaplastic
astrocytoma and glioblastoma, respectively.
Recently, the efficacy of this pretargeting radioimmunotherapy
protocol was evaluated in an adjuvant setting (Grana et al, 2002).
Newly diagnosed patients, 17 with grade III glioma and 20 with
glioblastoma, received surgery and external beam radiation. Then,
19 patients received the three reagents in the sequence described
above with the
90Y-labelled biotin being given at a dose of
2.2GBqm
 2, with the remaining 18 patients serving as controls.
Unlike the initial clinical study, all reagents were administered via
the intravenous route instead of directly into the surgical resection
cavity. The median survival estimated for the grade IV glioma
patients was 8 months in the control group (n¼12) and 33.5
months in the treated group (n¼8). Only two of the 11 treated
grade III patients had died at the time of that publication.
The results obtained with this pretargeting protocol are highly
encouraging, particularly in light of the fact that significant
survival prolongation could be obtained even when then labelled
compound was administered intravenously. Furthermore, it was
discovered after completion of this trial that the BC-4 mAb
hybridoma clone produced an additional nonfunctional light chain
(De Santis et al, 2003). To solve this problem, a new anti-tenascin
mAb, ST2146, has been generated. A multi-centre clinical trial is
currently being planned to evaluate the therapeutic potential of
pretargeted radioimmunotherapy, with ST2146 mAb providing the
tenascin targeting component.
RADIOLABELLED PEPTIDES
Owing to the infiltrative nature of glioma, methods must be
devised for improving the delivery of targeted radiotherapy to
tumour cells that are distant from the primary lesion. One of the
limitations of mAbs is that they diffuse slowly through tissue as a
consequence of their large molecular size. Peptides can have
molecular weights two orders of magnitude less than intact mAbs
and thus are attractive carrier molecules for the targeted
irradiation of distant tumour cells. This strategy is currently being
investigated in patients with low-grade gliomas, many of which
overexpress somatostatin type 2 receptors (Hofer et al, 2001;
Schumacher et al, 2002).
Five patients with progressive gliomas (two WHO grade II, three
WHO grade III) and five patients with surgically debulked WHO
grade II gliomas were treated with the labelled somatostatin
analogue [
90Y]-DOTA
0-D-Phe
1-Tyr
3-octreotide. Patients received
between one and five cycles of the labelled peptide at a cumulative
activity of 555–7030MBq (15–190mCi). Responses of 13–45
months duration were observed in the progressive patients.
Disease stabilisation was observed in the five newly diagnosed
low-grade glioma patients who received radiolabelled peptide
therapy following resection. Side effects included increased seizure
frequency and were transient. However, the potential clinical role
of target radiotherapy in lower grade gliomas is less clear, because
a wait-and-see attitude currently prevails for patients with these
malignancies.
CONCLUSIONS AND FUTURE PERSPECTIVES
In summary, clinical trials, primarily with radiolabelled anti-
tenascin mAbs, have demonstrated the feasibility of performing
targeted radiotherapy in glioma patients. By administering the
labelled mAb directly into surgically created resection cavities, a
significant survival advantage has been obtained for patients with
malignant glioma in comparison with radiation therapy combined
with chemotherapy. Furthermore, we have shown that
131I–
labelled 81C6 results in significantly lower toxicity than other
techniques designed to boost radiation dose to the primary tumour
site such as stereotactic radiosurgery or brachytherapy.
It remains to be ascertained whether multiple cycles of targeted
radiotherapeutic offer a significant survival advantage compared
with single-dose protocols. Likewise, it is not clear whether longer
range beta emitters such as
90Y or shorter range beta emitters such
as
131I provide the best balance between maximising tumour cell
killing and minimising debilitating toxicity to normal brain. The
most intriguing challenge for targeted brain tumour radiotherapy
will be to develop strategies for delivering curative doses of
radiation to small deposits and single glioma cells located
centimetres from the primary lesion. Work to date with highly
cytotoxic alpha emitters and highly diffusible peptides is encoura-
ging in this regard. Use of micro-infusion techniques such as those
being used to treat gliomas with immunotoxins (Nguyen et al,
2003) may also play an important role.
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